Why Is Applied Therapeutics Stock Trading Higher Today? - Ap

Applied Therapeutics surges as FDA grants Priority Review to govorestat (AT-007) for Galactosemia treatment. If approved, it would be the first medication for Galactosemia. APLT also submits MAA to EMA, with a decision expected in Q4 2024. Private placement of $100 million.

Related Keywords

, European Medicines Agency , Committee For Medicinal Products Human , New Drug Application , Priority Review , Prescription Drug User Free Act , Pediatric Rare Disease , Priority Review Voucher , Applied Therapeutic , Marketing Authorization Application , Classic Galactosemia , Medicinal Products , Applied Therapeutics , Private Placement , Advanz European ,